Skip to main content

Table 4 Most common any-grade (≥ 25% of patients) and grade 3/4 (≥ 5% of patients) TEAEs

From: Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk

  Any grade Grade 3/4
  Standard risk High riska Standard risk High riska
TEAE, n (%) D-Vd (n = 137) Vd (n = 136) D-Vd (n = 40) Vd (n = 34) D-Vd (n = 137) Vd (n = 136) D-Vd (n = 40) Vd (n = 34)
Hematologic
 Thrombocytopenia 85 (62) 58 (43) 24 (60) 16 (47) 65 (47) 45 (33) 19 (48) 12 (35)
 Anemia 45 (33) 41 (30) 7 (18) 14 (41) 25 (18) 23 (17) 4 (10) 6 (18)
 Neutropenia 29 (21) 16 (12) 9 (23) 3 (9) 21 (15) 6 (4) 6 (15) 2 (6)
 Lymphopenia 18 (13) 5 (4) 4 (10) 4 (12) 14 (10) 3 (2) 3 (8) 3 (9)
 Leukopenia 15 (11) 5 (4) 3 (8) 3 (9) 5 (4) 1 (1) 1 (3) 2 (6)
Nonhematologic
 Peripheral sensory neuropathy 67 (49) 50 (37) 22 (55) 13 (38) 4 (3) 8 (6) 2 (5) 4 (12)
 Upper respiratory tract infection 43 (31) 20 (15) 15 (38) 8 (24) 1 (1) 0 3 (8) 1 (3)
 Diarrhea 42 (31) 35 (26) 11 (28) 6 (18) 6 (4) 2 (2) 1 (3) 0
 Cough 40 (29) 19 (14) 9 (23) 4 (12) 0 0 0 0
 Fatigue 25 (18) 40 (29) 17 (43) 8 (24) 6 (4) 5 (4) 2 (5) 1 (3)
 Back pain 24 (18) 15 (11) 13 (33) 1 (3) 3 (2) 0 1 (3) 0
 Insomnia 22 (16) 20 (15) 11 (28) 5 (15) 2 (2) 0 0 1 (3)
 Pneumonia 22 (16) 20 (15) 5 (13) 4 (12) 15 (11) 14 (10) 2 (5) 3 (9)
 Asthenia 15 (11) 19 (14) 4 (10) 9 (27) 1 (1) 3 (2) 0 1 (3)
 Hypertension 15 (11) 5 (4) 4 (10) 1 (3) 9 (7) 1 (1) 2 (5) 0
 Decreased appetite 14 (10) 8 (6) 10 (25) 1 (3) 0 1 (1) 1 (3) 0
 Spinal pain 4 (3) 3 (2) 2 (5) 0 1 (1) 0 2 (5) 0
 Gastroenteritis 2 (2) 3 (2) 2 (5) 1 (3) 0 2 (2) 2 (5) 1 (3)
 Squamous cell carcinoma of the skin 0 0 2 (5) 0 0 0 2 (5) 0
  1. TEAE treatment-emergent adverse event, D-Vd daratumumab/bortezomib/dexamethasone, Vd bortezomib/dexamethasone
  2. aPatients with high cytogenetic risk had a t(4;14), t(14;16), or del17p abnormality